TCP-25

N/A

Report date: 2026/05/21 20:00:22
NME

Base Information

Drug NameTCP-25
Drug Alias NameBioC gelTCP-25
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionLipopolysaccharide (LPS) modulatorsMonocyte differentiation antigen CD14 modulators
TargetsLipopolysaccharide (LPS)Monocyte differentiation antigen CD14
Therapy Area/IndicationsWounds and InjuriesBlisterEpidermolysis Bullosa, Junctional +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySwedenItalyFrance +[5] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesLund University
China Registration ClassN/A

Develop Information

Active CompaniesXinnate AB
Inactive CompaniesN/A
Active IndicationsWounds and InjuriesBlisterEpidermolysis Bullosa, Junctional +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A